Use of biogenic estrogen sulfamates for hormone replacement therapy
CA 2338558 A1 · Owner: Schwarz, Sigfrid · Inventors: Schwarz, Sigfrid; Zimmermann, Holger; Elger, Walter
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to the use of biogenic estrogen sulfamates for the oral discontinuous application for hormone replacement therapy (HRT). The discontinuous administration takes place in intervals ranging from 2 to 40 days. The invention also provides the additional application of gestagens preferably continuously in the form of an implant or in the form of an intrauterine releasing system (IUD). Estrone sulfamate estradiol sulfamate or , an N-acyl sulfamate of estrone estradiol or estriol having up to 7 C-atoms in the acyl chain, or a combination comprised of two or more of said active ingredients are used as biogenic estrogen sulfamates.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 13, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 13, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 13, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.